CLINICAL TRIALS PROFILE FOR ELOCON
✉ Email this page to a colleague
All Clinical Trials for ELOCON
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00763529 ↗ | Elocon vs Fluticasone in Localized Psoriasis (P03197) | Completed | Merck Sharp & Dohme Corp. | Phase 4 | 2003-01-01 | This is an open-label, randomized, parallel-group clinical study. The primary objective is to assess the difference in response rate between mometasone furoate cream 0.1% (once daily) vs fluticasone propionate cream 0.05% (twice daily) by the end of Day 4 and Day 8 in the management of Indian patients with localized psoriasis. |
NCT00763529 ↗ | Elocon vs Fluticasone in Localized Psoriasis (P03197) | Completed | Schering-Plough | Phase 4 | 2003-01-01 | This is an open-label, randomized, parallel-group clinical study. The primary objective is to assess the difference in response rate between mometasone furoate cream 0.1% (once daily) vs fluticasone propionate cream 0.05% (twice daily) by the end of Day 4 and Day 8 in the management of Indian patients with localized psoriasis. |
NCT01108198 ↗ | Treatment of Phimosis With Topical Steroid Cream -Double-blind, Randomized, Placebo-controlled Study | Unknown status | University of Oulu | Phase 4 | 2006-10-01 | During last years topical steroid creams have been suggested to be effective treatment for non-retractable foreskin instead of circumcision. Aim of this study is to investigate the efficacy, safety and persistence of treatment results of a medium potent steroid cream in a double-blind, randomized, placebo-controlled study. |
NCT02973776 ↗ | Vasoconstriction Trial With LEO 90100 Aerosol Foam | Completed | LEO Pharma | Phase 1 | 2016-12-01 | Vasoconstriction study with LEO 90100 |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ELOCON
Condition Name
Clinical Trial Locations for ELOCON
Clinical Trial Progress for ELOCON
Clinical Trial Phase
Clinical Trial Sponsors for ELOCON
Sponsor Name